Icecure Medical Ltd
ICCM
View Detailed Chart
1.050USD
+0.010+0.96%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
61.63MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.96%
5 Days
+6.54%
1 Month
+22.09%
6 Months
-29.05%
Year to Date
-4.55%
1 Year
+61.54%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
2.590
Target Price
+149.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.29M.
Fairly Valued
The company’s latest PE is -3.74, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 28.04M shares, increasing 0.20% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.36.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Ticker SymbolICCM
CompanyIcecure Medical Ltd
CEOMr. Eyal Shamir
Websitehttps://icecure-medical.com/
Related Instruments
-0.38%
+0.66%
-0.50%
-1.05%
-0.38%
-0.20%
-0.04%
-1.03%
+1.23%
-0.60%
-1.76%
-0.27%
-2.84%
-1.19%
-0.78%
-0.30%
+0.98%
-0.76%
-1.25%
-3.23%
